Here are the 10-K annual reports from Q/C Technologies, Inc. (QCLS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow QCLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QCLS filings page.
Q/C Technologies, Inc. files Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III disclosures on directors, executive compensation, ownership and related-party transactions. The company reports an aggregate market value of non‑affiliate common equity of $3,616,742 on June 30, 2025, based on a $12.28 share price, and 7,853,429 common shares outstanding as of April 27, 2026.
The filing describes an eight‑member board, with a majority meeting Nasdaq independence standards and four standing committees overseeing audit, compensation, nominating/governance, and risk/disclosure. 2025 compensation for named executives includes $392,128 for Chief Medical Officer Mitchell Glass, $166,545 for Interim CFO Ian Rhodes, and $675,220 for Executive Chairman Joshua Silverman, reflecting cash salary plus equity awards such as restricted stock units and options.
The company highlights its 2021 Equity Incentive Plan authorizing 1,400,000 shares, with 1,064,166 shares remaining available as of December 31, 2025. Beneficial ownership data show concentrated holdings by entities such as PharmaCyte Biotech, Inc. and Premas Biotech PVT Ltd. The amendment also discloses several private placements of preferred stock and warrants and consulting agreements with related parties, all subject to the firm’s Code of Business Ethics and Conduct.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.